Project: Restoring endocannabinoid homeostasis to create the first effective & safe pharmacotherapy for PTSD
| Acronym | EndoCARE (Reference Number: 114985) |
| Duration | 03/02/2021 - 03/08/2023 |
| Project Topic | EndoCARE aims to develop the first safe and effective pharmacotherapy for Post-Traumatic Stress Disorder (PTSD) based on our unique Selective Endocannabinoid Reuptake Inhibitor (SERI) SYT-510. With a novel mode of action (MoA), SYT-510 restores physiological endocannabinoid (ECx) levels. Here, we combine MoA research with efficacy studies in novel PTSD animal model and preclinical neuroimaging and biomarker discovery, enabling a translational preclinical package to derisk our clinical programme. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Academic University Medical Center Amsterdam | Partner | Netherlands |
| 2 | Charles River Laboratories Den Bosch BV | Partner | Netherlands |
| 3 | Porsolt SAS | Partner | France |
| 4 | Pronexus Analytical AB | Partner | Sweden |
| 5 | Synendos Therapeutics AG | Coordinator | Switzerland |